Biotechnology - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

1 to 25 of 185 results

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

CMC Biologics and OncoSynergy link on Ebola drug development and manufacture

16-12-2014

Denmark and USA-based contract manufacturers CMC Biologics and US biopharma start-up OncoSynergy have…

Anti-viralsBiotechnologyCMC BiologicsOncoSynergyOS2966ProductionResearchTropical diseases

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

10-12-2014

US law firm Chimicles & Tikellis of Haverford, PA, has filed a law suit on behalf of the Southeastern…

Anti-viralsBiotechnologyGilead SciencesLawLegalPricingSocial IssuesSovaldiUnited StatesUSA

US declaration under PREP Act to support Ebola vaccines development

10-12-2014

US Health and Human Services Secretary Sylvia Burwell yesterday announced a declaration under the Public…

Anti-viralsBavarian NordicBiotechnologyGlaxoSmithKlineJanssenJohnson & JohnsonLegalNewLink GeneticsResearchTropical diseasesUSAVaccines

Government action needed to slash prices for hepatitis C treatments, says US advocacy

Government action needed to slash prices for hepatitis C treatments, says US advocacy

04-12-2014

The US federal government should act to dramatically lower the cost of new and prohibitively pricey medications…

Anti-viralsBiotechnologyGilead SciencesPricingSovaldiUSA

Cocrystal Pharma and RFS Pharma complete merger

28-11-2014

USA-based biotech firm Cocrystal Pharma has announced the closing of its merger with RFS Pharma, a privately…

Anti-viralsBiotechnologyCocrystal PharmaMergers & AcquisitionsRFS Pharma

Merck gains rights to NewLink Genetics investigational Ebola vaccine

24-11-2014

US pharma giant Merck & Co has entered into an exclusive worldwide license agreement to research, develop,…

Anti-viralsBiotechnologyGlobalLicensingMerck & CoNewLink GeneticsResearchrVSV-EBOYTropical diseases

Gilead Sciences’ Harvoni gains EU approval

Gilead Sciences’ Harvoni gains EU approval

19-11-2014

The European Commission yesterday granted marketing authorization for US biotech antiviral specialists…

Anti-viralsBiotechnologyEuropeGilead SciencesHarvoniRegulationSovaldi

Scripps Research Institute scientists reveal weak spots in Ebola's defenses

18-11-2014

Scientists at The Scripps Research Institute (TSRI) have identified weak spots on the surface of Ebola…

Anti-viralsBiotechnologyMapp BiopharmaceuticalResearchTropical diseasesZMapp

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014

US surveyed specialists anticipate prescribing Gilead Sciences’ Harvoni to a high proportion of their…

Anti-viralsBiotechnologyGilead SciencesHarvoniJanssenMarkets & MarketingMedivirOlysioSovaldiUSA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

06-11-2014

The Food and Drug Administration has approved US health care giant Johnson & Johnson's Olysio (simeprevir)…

Anti-viralsBiotechnologyJohnson & JohnsonMedivirOlysioRegulationsofosbuvirUSA

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

31-10-2014

The US Department of Defense has contracted the manufacture and IND-enabling preclinical testing of the…

Anti-viralsBiotechnologyProfectus BioSciencesResearchUSAVesiculoVax Zaire-Ebola

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

Gilead third-qtr sales beat expectations, but Sovaldi disappoints

29-10-2014

There was mixed news late yesterday from US anti-virals major Gilead Sciences, when the biotech posted…

Anti-viralsBiotechnologyFinancialGilead SciencesHarvoniSovaldiUSA

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

23-10-2014

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniMarkets & MarketingPricingSovaldiUSA

Profectus BioSciences gets US government funding for Ebola vaccine development

17-10-2014

Under a one-year contract with US biotech firm Profectus BioSciences, the US Department of Health and…

Anti-viralsBiotechnologyFinancialProfectus BioSciencesResearchUSA

Imaxio signs option for a license agreement with DKFZ

14-10-2014

French vaccine focussed biotech firm Imaxio has signed an option for a license agreement with the German…

Anti-viralsBiotechnologyImaxioLicensingResearch

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

FDA approves Gilead’s Harvoni, the first combo pill for hepatitis C

12-10-2014

As was largely expected, the US Food and Drug Administration on Friday approved biotech firm Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniPricingRegulationSovaldiUSA

Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

Chimerix reports preliminary data showing antiviral brincidofovir improves survival in adenovirus

09-10-2014

Antiviral biopharma company Chimerix has reported preliminary data indicating that its investigational…

Anti-viralsBiotechnologybrincidofovirChimerixResearchUSA

AfriCoLeish launches Phase III study on Gilead's AmBisome in treatment of visceral leishmaniasis

AfriCoLeish launches Phase III study on Gilead's AmBisome in treatment of visceral leishmaniasis

06-10-2014

AfriCoLeish, the international research and development consortium formed by six research organizations…

AfriCoLeishAmbisomeAnti-viralsBiotechnologyEthiopiaGilead SciencesResearch

Gilead files for Japanese approval of ledipasvir/sofosbuvir for hepatitis C

24-09-2014

Gilead Sciences has submitted a New Drug Application to Japan’s Pharmaceutical and Medical Devices…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationsofosbuvir

Gilead's TAF-based HIV regimen meets 48-week primary objective

Gilead's TAF-based HIV regimen meets 48-week primary objective

24-09-2014

Gilead Sciences says that two Phase III clinical trials (Studies 104 and 111) evaluating an investigational…

Anti-viralsBiotechnologyGilead SciencesResearchtenofovir alafenamideUSA

SIGA Technologies files for Chapter 11 reorganization

SIGA Technologies files for Chapter 11 reorganization

16-09-2014

Biological warfare defense firm SIGA Technologies has filed a voluntary petition for relief under chapter…

Anti-viralsBiotechnologyFinancialLegalPharmAtheneSIGA TechnologiesTecovirimatUSA

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

1 to 25 of 185 results

Back to top